The main objective of this study is to compare conventional chemotherapy: daunorubicin and the Aracytine and this chemotherapy in combination with the monoclonal antibody used Mylotarg in divided doses.

Patients with a morphologically proven diagnosis AML and both the two following criteria:

• Age > 50 years and £ 70 years.
• Not previously treated for their disease.

Randomization will be centralized by phone :

Arm A chemotherapy with daunorubicin and Aracytine or Arm B Daunorubicin and Aracytine and Mylotarg.

Inclusion Criteria:

• Patients with a morphologically proven diagnosis AML and both the two following criteria: Age > 50 years and £ 70 years. Not previously treated for their disease.
• ECOG performance status 0 to 3
• Negative serology HIV, HBV and HBC (except post vaccination)
• Serum creatinin inf 2.5N; AST and ALT inf 2.5N; total bilirubin inf 2N
• Cardiac function determined by radionucleide or echography within normal limits.
• Negative serum pregnancy test within one week before treatment for women of child bearing potential.
• Signed informed consent.

Exclusion Criteria:

• M3-AML
• AML following previously know myeloproliferative syndrome.
• Known central nervous system involvement.
• Uncontrolled infection
• Other active malignancy